CA2362914A1 - Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections - Google Patents
Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections Download PDFInfo
- Publication number
- CA2362914A1 CA2362914A1 CA002362914A CA2362914A CA2362914A1 CA 2362914 A1 CA2362914 A1 CA 2362914A1 CA 002362914 A CA002362914 A CA 002362914A CA 2362914 A CA2362914 A CA 2362914A CA 2362914 A1 CA2362914 A1 CA 2362914A1
- Authority
- CA
- Canada
- Prior art keywords
- dideoxy
- imino
- substituted
- hepatitis virus
- treating hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula (I) are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula (I) may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11985699P | 1999-02-12 | 1999-02-12 | |
US11972299P | 1999-02-12 | 1999-02-12 | |
US60/119,856 | 1999-02-12 | ||
US60/119,722 | 1999-02-12 | ||
PCT/US2000/003768 WO2000047198A2 (en) | 1999-02-12 | 2000-02-14 | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2362914A1 true CA2362914A1 (en) | 2000-08-17 |
CA2362914C CA2362914C (en) | 2009-04-14 |
Family
ID=26817632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002362914A Expired - Fee Related CA2362914C (en) | 1999-02-12 | 2000-02-14 | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
Country Status (10)
Country | Link |
---|---|
US (3) | US6545021B1 (en) |
EP (1) | EP1165080A2 (en) |
JP (1) | JP2002536407A (en) |
AT (1) | ATE402701T1 (en) |
AU (1) | AU3595500A (en) |
CA (1) | CA2362914C (en) |
DE (1) | DE60039729D1 (en) |
ES (1) | ES2311921T3 (en) |
HK (1) | HK1043311A1 (en) |
WO (1) | WO2000047198A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689759B1 (en) | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
EP1173161A2 (en) | 1999-02-12 | 2002-01-23 | G.D. SEARLE & CO. | Glucamine compounds for treating hepatitis virus infections |
AU1840101A (en) | 1999-08-10 | 2001-03-05 | Chancellor, Masters And Scholars Of The University Of Oxford, The | Long chain n-alkyl compounds and oxo-derivatives thereof |
US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
JP2003522791A (en) * | 2000-02-14 | 2003-07-29 | ファルマシア コーポレイション | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for the treatment of hepatitis virus infection |
BR0114837A (en) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | modified nucleosides for treatment of viral infections and abnormal cell proliferation |
US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
KR20050092103A (en) * | 2002-09-23 | 2005-09-20 | 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 | Use of iminosugar derivatives to inhibit ion channel activity |
US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
WO2006125141A2 (en) | 2005-05-17 | 2006-11-23 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives |
US20080138351A1 (en) * | 2006-08-02 | 2008-06-12 | United Therapeutics Corporation | Liposome treatment of viral infections |
CA2666814A1 (en) * | 2006-08-21 | 2008-05-29 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
US8097728B2 (en) * | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
CN102046151A (en) * | 2008-03-26 | 2011-05-04 | 牛津大学 | Endoplasmic reticulum targeting liposomes |
WO2010027996A1 (en) * | 2008-09-02 | 2010-03-11 | Institute For Hepatitis And Virus Research | Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity |
AT507745B1 (en) * | 2008-12-16 | 2012-01-15 | Forschungsholding Tu Graz Gmbh | FLUOROPHILE GLYCOSIDASE INHIBITOR |
CN102655746B (en) | 2009-02-23 | 2016-08-03 | 联合治疗公司 | Iminosugar and the method for the treatment of viral disease |
CA2753194A1 (en) * | 2009-02-24 | 2010-09-02 | United Therapeutics Corporation | Iminosugars and methods of treating arenaviral infections |
WO2010109330A2 (en) * | 2009-03-27 | 2010-09-30 | University Of Oxford | Cholesterol level lowering liposomes |
KR101463661B1 (en) | 2009-06-12 | 2014-11-19 | 유나이티드 세러퓨틱스 코오포레이션 | Iminosugars and methods of treating bunyaviral and togaviral diseases |
EP2473482B1 (en) * | 2009-09-04 | 2014-03-05 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
JP5575246B2 (en) * | 2009-09-04 | 2014-08-20 | ユナイテッド セラピューティクス コーポレイション | How to treat poxvirus infection |
EP2473046B1 (en) * | 2009-09-04 | 2014-10-22 | United Therapeutics Corporation | Iminosugars for their use in the treatment of filoviral diseases |
KR20140135222A (en) | 2012-03-07 | 2014-11-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
IN2014MN02539A (en) | 2012-06-06 | 2015-07-24 | Unither Virology Llc | |
SG11201601646YA (en) | 2013-09-16 | 2016-04-28 | Emergent Virology Llc | Deoxynojirimycin derivatives and methods of their using |
US9598438B2 (en) * | 2014-02-12 | 2017-03-21 | Amicus Therapeutics, Inc. | Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC |
CR20170107A (en) | 2014-09-30 | 2017-09-01 | Amicus Therapeutics Inc | VERY POWERFUL ACID ALFA-GLUCOSIDASE WITH POTENTIATED CARBON HYDRATES |
EP3215499B1 (en) | 2014-11-05 | 2021-01-20 | Emergent Virology LLC | Iminosugars useful for the treatment of viral diseases |
SG11201804965SA (en) | 2015-12-30 | 2018-07-30 | Amicus Therapeutics Inc | Augmented acid alpha-glucosidase for the treatment of pompe disease |
IL283430B (en) | 2016-03-30 | 2022-07-01 | Amicus Therapeutics Inc | Formulations comprising recombinant acid alpha-glucosidase |
IL295551A (en) | 2016-03-30 | 2022-10-01 | Amicus Therapeutics Inc | Method for selection of high m6p recombinant proteins |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
GB1555654A (en) | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
US4065562A (en) | 1975-12-29 | 1977-12-27 | Nippon Shinyaku Co., Ltd. | Method and composition for reducing blood glucose levels |
US4012448A (en) | 1976-01-15 | 1977-03-15 | Stanford Research Institute | Synthesis of adriamycin and 7,9-epiadriamycin |
NO154918C (en) | 1977-08-27 | 1987-01-14 | Bayer Ag | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE. |
GB2020278B (en) | 1978-05-03 | 1983-02-23 | Nippon Shinyaku Co Ltd | Moranoline dervitives |
JPS5562004A (en) | 1978-11-02 | 1980-05-10 | Kureha Chem Ind Co Ltd | Control agent against plant viral disease |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
DE3049446A1 (en) * | 1980-12-30 | 1982-07-29 | Bayer Ag, 5090 Leverkusen | METHOD FOR PRODUCING 1,5-DIDESOXY-1,5-IMINO-D-GLUCITOL AND ITS N-DERIVATIVES |
ZA822995B (en) | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
DE3650377T2 (en) | 1985-12-23 | 1996-02-22 | Hutchinson Fred Cancer Res | REGULATION OF RETROVIRAL REPLICATION, INFECTION AND PATHOGENESIS. |
GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
DE3611841A1 (en) | 1986-04-09 | 1987-10-15 | Bayer Ag | METHOD FOR PRODUCING 1-DESOXYNOJIRIMYCIN AND ITS N-DERIVATIVES |
US5039667A (en) * | 1987-08-07 | 1991-08-13 | The Governors Of The University Of Alberta | Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides |
US4848430A (en) * | 1987-09-28 | 1989-07-18 | Leski Lenet | Tire snow belt |
DE3814549A1 (en) * | 1987-10-30 | 1989-05-18 | Bayer Ag | N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS |
DE3737523A1 (en) * | 1987-11-05 | 1989-05-18 | Bayer Ag | USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS |
PT89266B (en) | 1987-12-21 | 1993-11-30 | Monsanto Co | METHOD FOR INHIBITING VIRUSES OF HUMAN IMMUNODEFICIENCY USING A D-N-N-BUTOTE OF DESOXYJYRIMYCIN |
US4849430A (en) | 1988-03-09 | 1989-07-18 | Monsanto Company | Method of inhibiting virus |
FI101344B1 (en) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Process for the preparation of a composition for controlled release of a pharmaceutically active substance |
US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
EP0350012A3 (en) | 1988-07-08 | 1990-09-05 | Meiji Seika Kaisha Ltd. | Antiviral composition |
US5144037A (en) | 1988-11-03 | 1992-09-01 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-d-glucitol derivatives |
US5310745A (en) | 1988-11-03 | 1994-05-10 | G. D. Searle & Co. | Antiviral compounds |
US5003072A (en) * | 1988-11-03 | 1991-03-26 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
US5221746A (en) | 1988-11-03 | 1993-06-22 | G. D. Searle & Co. | 1,5-dideoxy-1,5-imino-D-glucitol derivatives |
US4957926A (en) | 1988-12-22 | 1990-09-18 | Monsanto Company | Method of treating herpesviruses |
US5132291A (en) * | 1989-01-24 | 1992-07-21 | Gensia Pharmaceuticals, Inc. | Antivirals and methods for increasing the antiviral activity of azt |
US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
CA2065446A1 (en) * | 1989-09-07 | 1991-03-08 | Yoshiaki Yoshikuni | Antiviral drug |
US5030638A (en) | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
DE4009561A1 (en) | 1990-03-24 | 1991-09-26 | Bayer Ag | New anti-retroviral desoxy:nojirimycin derivs. |
US5536732A (en) | 1990-04-27 | 1996-07-16 | Merrell Pharmaceuticals Inc. | N-derivatives of 1-deoxy nojirimycin |
US5151519A (en) | 1990-05-07 | 1992-09-29 | G. D. Searle & Co. | Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof |
ES2087277T3 (en) | 1990-09-20 | 1996-07-16 | Monsanto Co | PROCEDURE TO PRODUCE 1-N-SUBSTITUTED DEOXYNOJIRIMYCIN. |
US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
DE4307883A1 (en) | 1992-03-12 | 1993-09-23 | Westarp Martin Egon Dr Med | Use of anti-retroviral substances - to treat motor-neuronal diseases |
IL105090A (en) | 1992-03-18 | 1998-08-16 | Us Bioscience | N-(phosphonoacetyl)-l-aspartic acid as broad spectrum antiviral |
ZA931934B (en) | 1992-03-18 | 1993-03-18 | Us Bioscience | Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
US5331096A (en) | 1992-04-01 | 1994-07-19 | G. D. Searle & Co. | 2- and 3-sulfur derivatives of 1,5-iminosugars |
US5258518A (en) | 1992-04-01 | 1993-11-02 | G. D. Searle & Co. | 2-substituted tertiary carbinol derivatives of deoxynojirimycin |
US5261724A (en) * | 1992-04-03 | 1993-11-16 | Grammer Ag | Sprung seat |
EP0655457A1 (en) | 1992-08-14 | 1995-05-31 | Nippon Shinyaku Company, Limited | Moranoline derivative |
US5265356A (en) * | 1992-10-14 | 1993-11-30 | Winter Kent L | Snowplow and hydraulic system for same |
FR2700267B1 (en) | 1993-01-13 | 1995-03-17 | Oreal | N-acyl amino deoxy alditols, and their use in cosmetic or dermopharmaceutical compositions. |
WO1994021595A1 (en) | 1993-03-17 | 1994-09-29 | Kao Corporation | Amine derivative and dermatologic preparation containing the same |
US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
US5750648A (en) * | 1993-08-20 | 1998-05-12 | G.D. Searle & Co. | Retroviral protease inhibitors and combinations thereof |
AU7518694A (en) | 1993-08-20 | 1995-03-21 | G.D. Searle & Co. | Retroviral protease inhibitors and combinations thereof |
US6093702A (en) | 1993-12-20 | 2000-07-25 | The United States Of America As Represented By The Department Of Health And Human Services | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |
JP3628021B2 (en) * | 1994-01-13 | 2005-03-09 | ジー.ディー.サール アンド カンパニー | Use of N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol for the treatment of hepatitis B virus infection |
WO1995022975A1 (en) | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
US5451679A (en) | 1994-03-08 | 1995-09-19 | G. D. Searle & Co. | 2-chloro and 2-bromo derivatives of 1,5-iminosugars |
US5491261A (en) * | 1994-07-01 | 1996-02-13 | Ciba-Geigy Corporation | Poly-perfluoroalkyl-substituted alcohols and acids, and derivatives thereof |
US5622342A (en) * | 1994-10-26 | 1997-04-22 | Mills; James E. | Versatile apparatus for supporting cameras, spotting scopes and other devices |
US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
FR2731150B1 (en) | 1995-03-03 | 1997-04-18 | Oreal | USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA |
EP1655033A1 (en) * | 1995-06-07 | 2006-05-10 | Emory University | Nucleosides with anti-hepatitis B virus activity |
US5763470A (en) | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
WO1997000881A1 (en) | 1995-06-22 | 1997-01-09 | Nippon Shinyaku Co., Ltd. | Moranoline derivatives |
US5905068A (en) * | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US20030100532A1 (en) * | 1997-02-14 | 2003-05-29 | Gary S. Jacob | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
ATE295732T1 (en) * | 1997-02-14 | 2005-06-15 | Searle Llc | USE OF N-SUBSTITUTED 1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY OF INFECTIONS CAUSED BY HEPATITIS VIRUS |
KR20010033028A (en) * | 1997-12-11 | 2001-04-25 | 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 | Inhibition of membrane-associated viral replication |
US6689759B1 (en) * | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
ES2272054T3 (en) * | 1998-02-12 | 2007-04-16 | United Therapeutics Corporation | USE OF N-SUBSTITUTED-1,5-DIDESOXI-1,5-IMINO-D-GLUCITOL COMPOUNDS TO TREAT INFECTIONS BY HEPATITIS VIRUSES. |
US20040132161A1 (en) * | 1998-04-20 | 2004-07-08 | Finkel Terri H. | Methods and compositions for increasing CD4lymphocyte immune responsiveness |
EP1173161A2 (en) * | 1999-02-12 | 2002-01-23 | G.D. SEARLE & CO. | Glucamine compounds for treating hepatitis virus infections |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
-
2000
- 2000-02-14 EP EP00914585A patent/EP1165080A2/en not_active Withdrawn
- 2000-02-14 AU AU35955/00A patent/AU3595500A/en not_active Abandoned
- 2000-02-14 CA CA002362914A patent/CA2362914C/en not_active Expired - Fee Related
- 2000-02-14 WO PCT/US2000/003768 patent/WO2000047198A2/en not_active Application Discontinuation
- 2000-02-14 AT AT05027240T patent/ATE402701T1/en not_active IP Right Cessation
- 2000-02-14 DE DE60039729T patent/DE60039729D1/en not_active Expired - Lifetime
- 2000-02-14 ES ES05027240T patent/ES2311921T3/en not_active Expired - Lifetime
- 2000-02-14 JP JP2000598151A patent/JP2002536407A/en active Pending
- 2000-02-14 US US09/503,945 patent/US6545021B1/en not_active Expired - Lifetime
-
2002
- 2002-06-28 HK HK02104874.1A patent/HK1043311A1/en unknown
-
2003
- 2003-01-14 US US10/341,717 patent/US20030220299A1/en not_active Abandoned
-
2006
- 2006-06-22 US US11/472,542 patent/US20060264468A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6545021B1 (en) | 2003-04-08 |
JP2002536407A (en) | 2002-10-29 |
US20060264468A1 (en) | 2006-11-23 |
CA2362914C (en) | 2009-04-14 |
AU3595500A (en) | 2000-08-29 |
WO2000047198A2 (en) | 2000-08-17 |
ATE402701T1 (en) | 2008-08-15 |
EP1165080A2 (en) | 2002-01-02 |
DE60039729D1 (en) | 2008-09-11 |
ES2311921T3 (en) | 2009-02-16 |
HK1043311A1 (en) | 2002-09-13 |
US20030220299A1 (en) | 2003-11-27 |
WO2000047198A3 (en) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2362914A1 (en) | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | |
CA2433878A1 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
BR9907882A (en) | Use of unsubstituted 1,5-dideoxy-1,5-imino-d-glucitol compounds for the treatment of hepatitis virus infections | |
TWI317735B (en) | Methods and compositions for treating hepatitis c virus | |
BR0307712A (en) | Compound, composition and use in the treatment of flaviviridae infections and abnormal cell proliferation | |
PL359169A1 (en) | Methods and compositions for treating flaviviruses and pestiviruses | |
EP1128832A4 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
WO2004002422A3 (en) | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
MXPA03008623A (en) | Pharmaceutical combinations for the treatment of cancer. | |
WO2002092006A3 (en) | Nucleic acid-based compounds and methods of use thereof | |
WO2001008672A3 (en) | Glucamine compounds for treating hepatitis virus infections | |
AU6169298A (en) | Use of (n)-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combinationtherapy for treating hepatitis virus infections | |
WO2003020222A3 (en) | PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE | |
WO2001070706A3 (en) | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents | |
WO2004064784A3 (en) | Composition and method for preventing or treating a virus infection | |
EP1714676A3 (en) | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | |
ZA991142B (en) | Use of N-substituted-1,5-dideoxy-1,5-imino-D-Glucitol compounds for treating hepatitis virus infections. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190214 |